[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588813":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":27,"responsibleParty":45,"collaborators":11,"id":47,"slug":11,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":11,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":11,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":11,"overallStatus":67,"whyStopped":11,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"China International Neuroscience Institution","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Dexmedetomidine Preemptive Analgesia","EXPERIMENTAL",null,[13],"Drug: Preemptive Analgesia Of Dexmedetomidine",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Preemptive Analgesia Of Dexmedetomidine","Preemptive Analgesia Of Dexmedetomidine 1.5 μg · kg-1·h-1 before operation",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Yanghai Cui, prof","CONTACT","+861083199270","+8618196987786","1055885750@qq.com",[28],{"facility":29,"status":11,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Xuanwu hospital","Beijing","Beijing Municipality","100053","China",{"type":35,"coordinates":36},"Point",[37,38],116.39723,39.9075,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":43,"phoneExt":44,"email":26},"Yanghai Cui, PHD","83199270","15010283592",{"type":46,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100588813",false,"NCT06946277","Assessing the Time-Course of Dexmedetomidine-Induced Analgesia Via EEG","Mapping the Temporal Profile of Dexmedetomidine-Induced Analgesia Via EEG Signatures in Brain","Inclusion Criteria:\n\nPatients with hip osteoarthritis scheduled for total hip arthroplasty under intrathecal anesthesia; Age 18-70 years; American Society of Anesthesiologists (ASA) physical status classification I-III; Body mass index (BMI) 22-30 kg\u002Fm².\n\nExclusion Criteria:\n\nPre-existing peripheral or central nervous system disorders; Mental disorders; Cognitive impairment; Emergency surgery; or Hearing impairment.","ALL","18 Years","70 Years",{"count":57,"type":58},20,"ESTIMATED","INTERVENTIONAL",[61],"PHASE4","Objective: To investigate the temporal dynamics of dexmedetomidine's analgesic effects in the brain using EEG.\n\nMethods: Eligible patients scheduled for total hip arthroplasty under intrathecal anesthesia received a continuous infusion of DEX at 1.5 μg\u002F(kg·h) for 15 minutes before neuraxial puncture, followed by an additional 15-minute infusion. The study was divided into three phases:\n\nPhase 1: Non-dosing phase (Baseline). Phase 2: DEX preemptive analgesia phase (DEX infusion). Phase 3: DEX cessation phase (Post-infusion).\n\nOutcomes:\n\nPrimary safety outcome: EEG spectral analysis at different phases. Secondary outcomes: NRS scores, postoperative nausea and vomiting (PONV), dizziness, agitation, and time to intestinal exhaust within 48 hours. Intraoperative hemodynamics were also monitored.",[64,65,66],"Total Hip Arthroplasty (THA)","Intrathecal Anesthesia","Hip Osteoarthritis","NOT_YET_RECRUITING","2025-04-23",{"date":70,"type":71},"2025-04-27","ACTUAL",{"date":73,"type":58},"2025-04-25",{"date":75,"type":58},"2025-05-26",{"name":5,"class":6},1]